IBDEI1D2 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24420,1,5,0)
 ;;=5^Varicose Veins
 ;;^UTILITY(U,$J,358.3,24420,2)
 ;;=^328758
 ;;^UTILITY(U,$J,358.3,24421,0)
 ;;=271.3^^145^1526^11
 ;;^UTILITY(U,$J,358.3,24421,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24421,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,24421,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,24421,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,24422,0)
 ;;=611.1^^145^1526^16
 ;;^UTILITY(U,$J,358.3,24422,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24422,1,4,0)
 ;;=4^611.1
 ;;^UTILITY(U,$J,358.3,24422,1,5,0)
 ;;=5^Gynecomastia
 ;;^UTILITY(U,$J,358.3,24422,2)
 ;;=^60454
 ;;^UTILITY(U,$J,358.3,24423,0)
 ;;=704.1^^145^1526^17
 ;;^UTILITY(U,$J,358.3,24423,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24423,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,24423,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,24423,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,24424,0)
 ;;=251.2^^145^1526^30
 ;;^UTILITY(U,$J,358.3,24424,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24424,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,24424,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,24424,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,24425,0)
 ;;=253.2^^145^1526^34
 ;;^UTILITY(U,$J,358.3,24425,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24425,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,24425,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,24425,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,24426,0)
 ;;=733.00^^145^1526^43
 ;;^UTILITY(U,$J,358.3,24426,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24426,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,24426,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,24426,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,24427,0)
 ;;=278.00^^145^1526^40
 ;;^UTILITY(U,$J,358.3,24427,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24427,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,24427,1,5,0)
 ;;=5^Obesity
 ;;^UTILITY(U,$J,358.3,24427,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,24428,0)
 ;;=278.01^^145^1526^39
 ;;^UTILITY(U,$J,358.3,24428,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24428,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,24428,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,24428,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,24429,0)
 ;;=250.80^^145^1526^10
 ;;^UTILITY(U,$J,358.3,24429,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24429,1,4,0)
 ;;=4^250.80
 ;;^UTILITY(U,$J,358.3,24429,1,5,0)
 ;;=5^DM Type II with LE Ulcer
 ;;^UTILITY(U,$J,358.3,24429,2)
 ;;=DM Type II with LE Ulcer^267846^707.10
 ;;^UTILITY(U,$J,358.3,24430,0)
 ;;=250.00^^145^1526^5
 ;;^UTILITY(U,$J,358.3,24430,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24430,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,24430,1,5,0)
 ;;=5^DM Type II Dm W/O Complications
 ;;^UTILITY(U,$J,358.3,24430,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,24431,0)
 ;;=250.40^^145^1526^6
 ;;^UTILITY(U,$J,358.3,24431,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24431,1,4,0)
 ;;=4^250.40
 ;;^UTILITY(U,$J,358.3,24431,1,5,0)
 ;;=5^DM Type II Dm with Nephropathy
 ;;^UTILITY(U,$J,358.3,24431,2)
 ;;=^267837^583.81
 ;;^UTILITY(U,$J,358.3,24432,0)
 ;;=250.50^^145^1526^9
 ;;^UTILITY(U,$J,358.3,24432,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24432,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,24432,1,5,0)
 ;;=5^DM Type II w/ PDR
 ;;^UTILITY(U,$J,358.3,24432,2)
 ;;=DM Type II w/ PDR^267839^362.02
 ;;^UTILITY(U,$J,358.3,24433,0)
 ;;=250.60^^145^1526^7
 ;;^UTILITY(U,$J,358.3,24433,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24433,1,4,0)
 ;;=4^250.60
 ;;^UTILITY(U,$J,358.3,24433,1,5,0)
 ;;=5^DM Type II Dm with Neuropathy
 ;;^UTILITY(U,$J,358.3,24433,2)
 ;;=^267841^357.2
 ;;^UTILITY(U,$J,358.3,24434,0)
 ;;=250.70^^145^1526^8
